Rockwell Medical Inc (Nasdaq:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today that four individual abstracts for Triferic have been selected by the National Kidney Foundation (NKF) for presentation at their Spring Clinical Meetings, March 26-29, 2015 at the Gaylord Texan in Dallas, Texas. Triferic is the Company’s recent FDA-approved iron-replacement drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis.
The following abstracts will be presented at the NKF meetings:
- Triferic Does Not Induce Oxidative Stress In CKD-HD: The PRIME Study; Poster #126
- Triferic Administered Via Dialysate Maintains Hemoglobin Long Term: Results Of The CRUISE Open-Label Studies; Poster #125
- Pharmacokinetics Of Triferic Administered IV To Healthy Volunteers; Poster #329
- Triferic Does Not Increase Pre-dialysis Hepcidin Or Iron Sequestration: The PRIME Study; Poster #124
The NKF Spring Clinical Meetings 2015 present a unique opportunity for renal health care providers to learn new developments related to all aspects of nephrology. It is designed for kidney doctors in the private sector and academia, fellows and residents with a special interest in kidney disease, general internists, pharmacists, physician assistants, nurse practitioners, nurses and technicians, social workers, and renal and clinical dietitians. An important objective of the conference is to present the latest insights into chronic kidney disease care. Participants will learn about new and evolving concepts related to kidney disease through a carefully designed combination of interesting courses, practical workshops, thought-provoking symposia and insightful debates incorporating the latest developments in clinical nephrology. (Original Source)
Shares of Rockwell closed today at $10.49, up $0.16 or 1.55%. RMTI has a 1-year high of $13.06 and a 1-year low of $8.10. The stock’s 50-day moving average is $10.58 and it’s 200-day moving average is $9.90.
On the ratings front, Rockwell has been the subject of a number of recent research reports. In a report issued on February 27, Brean Capital analyst Jonathan Aschoff maintained a Sell rating on RMTI, with a price target of $4, which represents a potential downside of 61.3% from where the stock is currently trading. Separately, on January 27, Summer Street’s James Molloy reiterated a Buy rating on the stock and has a price target of $25.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jonathan Aschoff and James Molloy have a total average return of 14.1% and 21.4% respectively. Aschoff has a success rate of 56.8% and is ranked #157 out of 3547 analysts, while Molloy has a success rate of 68.0% and is ranked #461.
In total, one research analyst has rated the stock with a Sell rating, 3 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $10.34 which is 91.0% above where the stock opened today.
Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.